Efficacy of dietary hempseed oil in patients with atopic dermatitis.

forr√°s: http://www.ncbi.nlm.nih.gov/pubmed/16019622


2015-02-17 14:28:48


BACKGROUND:

Hempseed oil is a rich and balanced source of omega-6 and omega-3 polyunsaturated fatty acids (PUFAs). Anecdotal evidence indicated that dietary hempseed oil might be useful in treating symptoms of atopic dermatitis.

PATIENTS AND METHODS:

Dietary hempseed oil and olive oil were compared in a 20-week randomized, single-blind crossover study with atopic patients. Fatty acid profiles were measured in plasma triglyceride, cholesteryl and phospholipid fractions. A patient questionnaire provided additional information on skin dryness, itchiness and usage of dermal medications. Skin transepidermal water loss (TEWL) was also measured.

RESULTS:

Levels of both essential fatty acids (EFAs), linoleic acid (18:2n6) and alpha-linolenic acid (18:3n3), and gamma-linolenic acid (GLA; 18:3n6) increased in all lipid fractions after hempseed oil, with no significant increases of arachidonic acid (20:4n6) in any lipid fractions after either oil. Intra-group TEWL values decreased (p=0.074), qualities of both skin dryness and itchiness improved (p=0.027) and dermal medication usage decreased (p=0.024) after hempseed oil intervention.

CONCLUSIONS:

Dietary hempseed oil caused significant changes in plasma fatty acid profiles and improved clinical symptoms of atopic dermatitis. It is suggested that these improvements resulted from the balanced and abundant supply of PUFAs in this hempseed oil.


Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain.

forr√°s: http://www.ncbi.nlm.nih.gov/pubmed/16449552


2015-02-17 14:24:16


OBJECTIVE: To review the literature concerning the physiology of the endocannabinoid system, current drug development of cannabinoid agonists, and current clinical research on the use of cannabinoid agonists for analgesia.

DATA SOURCES:Articles were identified through a search of MEDLINE (1966-August 2005) using the key words cannabis, cannabinoid, cannabi*, cannabidiol, nabilone, THC, pain, and analgesia. No search limits were included. Additional references were located through review of the bibliographies of the articles identified.

STUDY SELECTION AND DATA EXTRACTION:Studies of cannabinoid agonists for treatment of pain were selected and were not limited by pain type or etiology. Studies or reviews using animal models of pain were also included. Articles that related to the physiology and pharmacology of the endocannabinoid system were evaluated.

DATA SYNTHESIS:The discovery of cannabinoid receptors and endogenous ligands for these receptors has led to increased drug development of cannabinoid agonists. New cannabimimetic agents have been associated with fewer systemic adverse effects than delta-9-tetrahydrocannabinol, including recent development of cannabis medicinal extracts for sublingual use (approved in Canada), and have had promising results for analgesia in initial human trials. Several synthetic cannabinoids have also been studied in humans, including 2 cannabinoid agonists available on the international market.

CONCLUSIONS:Cannabinoids provide a potential approach to pain management with a novel therapeutic target and mechanism. Chronic pain often requires a polypharmaceutical approach to management, and cannabinoids are a potential addition to the arsenal of treatment options.


Immunomodulatory and therapeutic effects of Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients.

forr√°s: http://www.ncbi.nlm.nih.gov/pubmed/24050582


2015-02-17 14:13:19


Background: Multiple sclerosis (MS) is the most chronic and inflammatory disorder. Because of limited efficacy and adverse side effects, identifying novel therapeutic and protective agents is important. This study was aimed to assess the potential therapeutic effects of hemp seed and evening primrose oils as well as Hot-nature dietary intervention on RRMS patients.

METHODS AND MATERIALS:

In this double blind, randomized trial, 100 MS patients with EDSS<6 were allocated into 3 groups: "Group A" who received co-supplemented hemp seed and evening primrose oils with advised Hot-nature diet, "Group B" who received olive oil, "Group C" who received the co-supplemented oils. Mizadj, clinically EDSS and relapse rate as well as immunological factors (IL-4, IFN-ő≥ and IL-17) were assessed at baseline and after 6 months.

RESULTS:

Mean follow-up was 180¬Ī2.9 SD days (N=65, 23 M and 42 F aged 34.25¬Ī8.07 years with disease duration 6.80¬Ī4.33 years). There was no significant difference in studies parameters at baseline. After 6 months, significant improvements in Mizadj, EDSS and relapse rate were found in the groups A and C, while the group B showed a border significant decrease in relapse rate. Immunological parameters showed improvement in groups A and C, whereas there was worsening condition for group B after the intervention.

CONCLUSION:

The co-supplemented hemp seed and evening primrose oils with Hot-nature diet have beneficial effects in improving of clinical score in RRMS patients which were confirmed by immunological findings.

Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.


Az √©tkez√©si kendermagolaj hat√©konys√°ga az at√≥pi√°s dermatitiszben (kr√≥nikusan fenn√°ll√≥ bŇĎrgyullad√°s, amely a velesz√ľletett allergi√°s hajlam alapj√°n fejlŇĎdik ki) szenvedŇĎ betegekn√©l

forr√°s: http://www.ncbi.nlm.nih.gov/pubmed/16019622


2015-02-17 14:28:48


Callaway J1, Schwab U., Harvima I., Halonen P., Mykkänen O., Hyvönen P. Järvinen T.

1Department of Pharmaceutical Chemistry, University of Kuopio, [Gyógyszerészeti Kémiai Tanszék, Kuopi-i Egyetem], Finnország callaway@uku.fi

H√ĀTT√ČR: A kendermagolaj az omega-6 √©s az omega-3 t√∂bbsz√∂r√∂sen tel√≠tetlen zs√≠rsavak (PUFA ‚Äď polyunsaturated fatty acids) gazdag √©s kiegyens√ļlyozott forr√°sa. Nem hivatalos tudom√°nyos bizony√≠t√©kok arra utalnak, hogy az √©tkez√©si kendermagolaj hat√°sos lehet az at√≥pi√°s dermatitisz kezel√©s√©re.

BETEGEK √ČS ELJ√ĀR√ĀSOK: az √©tkez√©si kendermag olajat √©s az ol√≠va olajat egy 20 hetes, a betegeket v√©letlenszerŇĪen csoportba oszt√≥, egyszeresen vak, keresztezett vizsg√°lat sor√°n hasonl√≠tott√°k √∂ssze at√≥pi√°s p√°ciensekn√©l. A zs√≠rsav profilokat m√©rt√©k a plazma trigliceridben, a koleszterinben √©s a foszfolipid frakci√≥kban. Egy betegek sz√°m√°ra k√©sz√ľlt k√©rdŇĎ√≠v tov√°bbi inform√°ci√≥kkal szolg√°lt a bŇĎr sz√°razs√°g√°t, a viszketegs√©get √©s a bŇĎrgy√≥gy√°szati k√©sz√≠tm√©nyek haszn√°lat√°t illetŇĎen. Szint√©n m√©rt√©k a bŇĎr transzepiderm√°lis v√≠zvesztes√©g√©t (TEWL ‚Äď transepidermal water loss = bŇĎr√∂n kereszt√ľli vizveszt√©s).

EREDM√ČNYEK: az esszenci√°lis zs√≠rsavak (EFA-k ‚Äď essential fatty acids), a linol√©nsav (18:2n6) √©s az alfa-linol√©nsav (18:3n3) √©s a gamma- linol√©nsav (GLA 18:3n6) szintjei valamennyi zs√≠r frakci√≥ban n√∂vekedtek a kendermag olaj alkalmaz√°s√°t k√∂vetŇĎen, viszont egyik olaj eset√©ben sem volt sz√°mottevŇĎ az arachidonsav (20:4n6) n√∂veked√©s a zs√≠rfrakci√≥kban. A csoporton bel√ľli transzepiderm√°lis v√≠zvesztes√©gi (TEWL) √©rt√©kek cs√∂kkentek (p = 0,074), cs√∂kkent a bŇĎrsz√°razs√°g √©s a viszketegs√©g m√©rt√©ke is (p = 0,027), √©s m√©rs√©klŇĎd√∂tt a bŇĎrgy√≥gy√°szati k√©sz√≠tm√©nyek haszn√°lata (p = 0,024) a kendermagolajjal t√∂rt√©nŇĎ beavatkoz√°st k√∂vetŇĎen.

K√ĖVETKEZTET√ČSEK: az √©tkez√©si kendermagolaj jelentŇĎs v√°ltoz√°sokat id√©zett elŇĎ a plazma zs√≠rsav profilokban √©s jav√≠totta az at√≥pi√°s dermatitisz klinikai t√ľneteit. A felt√©telez√©sek szerint ezek a javul√°sok a kendermagolajban kiegyens√ļlyozott √©s bŇĎs√©ges mennyis√©gben megtal√°lhat√≥ t√∂bbsz√∂r√∂sen tel√≠tetlen zs√≠rsavaknak tudhat√≥ak be.


A meleg term√©szetŇĪ [Mizadj] √©trend immunmodul√°l√≥ (az immunrendszer erŇĎs√≠t√©s√©vel a szervezet √∂ngy√≥gy√≠t√≥ tev√©kenys√©g√©t beind√≠t√≥) √©s ter√°pi√°s hat√°sai, valamint k√∂z√∂s t√°pl√°l√©k kieg√©sz√≠tŇĎk√©nt kendermag- √©s liget sz√©pe olajjal t√∂rt√©nŇĎ beavatkoz√°s szkler√≥zis mul

forr√°s: http://www.ncbi.nlm.nih.gov/pubmed/24050582


2015-02-17 14:13:19


Rezapour-Firouzi S.1, Arefhosseini SR., Mehdi F. Meranghiz EM, Baradaran B., Sadeghihokmabad E., Mostafaei S., Fazljou SM, Torbati MA, Sanaie S, Zamani F.

1Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; School of Nutrition and Health, Tabriz University of Medical Sciences, Tabriz, Iran  [Idegtudom√°nyi Kutat√≥ K√∂zpont, Tabriz-i Orvostudom√°nyi Egyetem, Tabriz, Iran; T√°pl√°lkoz√°studom√°nyi √©s Eg√©szs√©g√ľgyi Kar, Tabriz-i Orvostudom√°nyi Egyetem, Tabriz, Iran. E-mail c√≠m: s.rfirozi@gmail.com

H√ĀTT√ČR: A szkler√≥zis multiplex (SM) a legink√°bb id√ľlt √©s gyullad√°sos rendelleness√©g. Korl√°tozott hat√©konys√°ga √©s k√°ros mell√©khat√°sai miatt √ļj ter√°pi√°s √©s v√©dŇĎ anyagok azonos√≠t√°s√°ra van sz√ľks√©g. Ennek a kutat√°snak az a c√©lja, hogy √©rt√©kelje a kendermag- √©s a liget sz√©pe olaj, valamint a meleg term√©szetŇĪ [Mizadj garam] √©trendi beavatkoz√°s lehets√©ges ter√°pi√°s hat√°sait az olyan szkler√≥zis multiplex-ben szenvedŇĎ betegekn√©l, akikn√©l v√°ltj√°k egym√°st a betegs√©g javul√°s√°nak √©s visszaes√©s√©nek szakaszai (RRMS = relapsing-remitting multiple sclerosis = szkler√≥zis multiplex egym√°st v√°lt√≥ visszaes√©ses ‚Äď javul√°si szakaszokkal].

 

ELJ√ĀR√ĀSOK √ČS ANYAGOK: Ebben a kettŇĎs vak, v√©letlenszerŇĪ k√≠s√©rletben 100 szkler√≥zis multiplexes beteget, akikn√©l a betegs√©g kiterjedts√©g√©nek √°llapota az EDSS sk√°l√°n < 6 volt (EDSS = Expanded Disability Status Scale = szkler√≥zis multiplexes betegekn√©l a betegs√©g kiterjedts√©g√©nek √°llapotsk√°l√°ja), 3 csoportba osztottak:

  • az ‚ÄěA Csoport‚ÄĚ, amely egy√ľttes t√°pl√°l√©k kieg√©sz√≠t√©sk√©nt kendermag- √©s liget sz√©pe olajat kapott √©s cs√≠pŇĎs √©trendet tan√°csoltak nekik;
  • a ‚ÄěB Csoport‚ÄĚ, amely ol√≠va olajat kapott, √©s
  • a ‚ÄěC Csoport‚ÄĚ, amely egy√ľttes t√°pl√°l√©k kieg√©sz√≠tŇĎ olajakat kapott.

 

A Mizadj-ot, a betegs√©g klinikai kiterjedts√©g√©nek √°llapota, a visszaes√©si ar√°ny, valamint immunol√≥giai t√©nyezŇĎk (IL-4: interleukin-4, IFN-y: interferon gamma √©s IL-17: interleukin-17) ker√ľltek √©rt√©kel√©sre a kiindul√°skor √©s 6 h√≥nap eltelt√©vel.

EREDM√ČNYEK: A k√∂vet√©ses k√∂z√©p√©rt√©k 180 ¬Ī 2,9 standard elt√©r√©ses nap volt (65 fŇĎ, ebbŇĎl 23 f√©rfi √©s 42 nŇĎ, √©letkoruk 34,25 ¬Ī 8,07 √©v, a betegs√©g tartama 6,80 ¬Ī 4,33 √©v). A kiindul√°skori kutat√°si param√©terekben nem volt jelentŇĎs elt√©r√©s. 6 h√≥nap eltelt√©vel az A √©s C csoportn√°l szignifik√°ns javul√°st tal√°ltak a Mizadj-ban, a betegs√©g kiterjedts√©g√©nek √°llapot√°ban √©s a visszaes√©si ar√°nyban, m√≠g a visszaes√©si ar√°nyt tekintve a B csoport a szignifik√°ns roml√°s hat√°r√°n volt. A beavatkoz√°st k√∂vetŇĎen az immunol√≥giai param√©terek javul√°st mutattak az A √©s a C csoportban, m√≠g √°llapotrosszabbod√°st a B csoportban.

K√ĖVETKEZTET√ČS: A kendermag- √©s a liget sz√©pe olajjal t√∂rt√©nŇĎ t√°pl√°l√©k kieg√©sz√≠t√©snek √©s a meleg term√©szetŇĪ √©trendnek j√≥t√©kony hat√°sai voltak az olyan szkler√≥zis multiplexben szenvedŇĎ betegekre, akikn√©l v√°ltj√°k egym√°st a javul√°si-visszaes√©si szakaszok, √©s ezt immunol√≥giai eredm√©nyek is megerŇĎs√≠tettek.


QR-CODE

Download image: Right click, "Image save as..."